A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme (Q48122681)

8 February 2018

title

A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme (English)

1 reference

8 February 2018

adaptive radiation therapy

main subject

0 references

0 references

1 reference

Mizuhiko Terasaki

1 reference

8 February 2018

Tomoko Eto

1 reference

8 February 2018

Shinji Nakashima

1 reference

8 February 2018

Yosuke Okada

1 reference

8 February 2018

Etsuyo Ogo

1 reference

8 February 2018

Yasuo Sugita

1 reference

8 February 2018

Takashi Tokutomi

1 reference

8 February 2018

Minoru Shigemori

1 reference

8 February 2018

publication date

17 July 2010

1 reference

8 February 2018

Journal of Neuro-Oncology

published in

1 reference

8 February 2018

volume

102

1 reference

8 February 2018

issue

1 reference

8 February 2018

page(s)

247-253

1 reference

8 February 2018

Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Alpha/beta ratio: A dose range dependence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Short course radiotherapy is an appropriate option for most malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Dose escalation of whole-brain radiotherapy for brain metastases from melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Radiation dose-volume effects of optic nerves and chiasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0306-6

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20640480

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20640480

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-010-0306-6

1 reference

8 February 2018

1 reference

8 February 2018